Can we eradicate trachoma? A survey of stakeholders.

Anti-Bacterial Agents / administration & dosage Azithromycin / administration & dosage Disease Eradication Global Health Health Care Surveys Health Plan Implementation / organization & administration Humans Prevalence Preventive Health Services / organization & administration Trachoma / epidemiology World Health Organization
Cornea Epidemiology Infection Public health

Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
08 2021
Historique:
received: 03 01 2020
accepted: 27 07 2020
revised: 25 07 2020
pubmed: 29 8 2020
medline: 25 9 2021
entrez: 29 8 2020
Statut: ppublish

Résumé

Although tremendous progress towards the 2020 goal of global elimination of trachoma as a public health problem has been made, it will not be achieved. Future targets are now being considered. One option is changing the goal to We conducted a survey at the beginning of a trachoma eradication session at the 2019 Coalition for Operational Research on Neglected Tropical Diseases meeting in National Harbor, Maryland, USA. We asked respondents what the most important goal of azithromycin mass drug administration was for trachoma (control, elimination of infection or eradication) and if and when they believed trachoma eradication would occur. We then asked what the biggest obstacles were to global eradication. Fifty-six surveys were returned (95%). Most (91%) participants reported that the most important goal of azithromycin mass drug administration was control or elimination of infection, and 24% of participants reported that global eradication was not possible. Of the 76% who reported a year by which they believed trachoma could be eradicated, most fell between 2040 and 2050. Commonly cited barriers to global eradication included lack of surveillance tools to confirm eradication or monitor for infection recrudescence (32%) and lack of resources (23%). Development of alternative indicators for trachoma surveillance and continued investment in trachoma programmes, particularly focused support in the most heavily affected populations, might increase enthusiasm for the feasibility of eradication.

Sections du résumé

BACKGROUND/AIMS
Although tremendous progress towards the 2020 goal of global elimination of trachoma as a public health problem has been made, it will not be achieved. Future targets are now being considered. One option is changing the goal to
METHODS
We conducted a survey at the beginning of a trachoma eradication session at the 2019 Coalition for Operational Research on Neglected Tropical Diseases meeting in National Harbor, Maryland, USA. We asked respondents what the most important goal of azithromycin mass drug administration was for trachoma (control, elimination of infection or eradication) and if and when they believed trachoma eradication would occur. We then asked what the biggest obstacles were to global eradication.
RESULTS
Fifty-six surveys were returned (95%). Most (91%) participants reported that the most important goal of azithromycin mass drug administration was control or elimination of infection, and 24% of participants reported that global eradication was not possible. Of the 76% who reported a year by which they believed trachoma could be eradicated, most fell between 2040 and 2050. Commonly cited barriers to global eradication included lack of surveillance tools to confirm eradication or monitor for infection recrudescence (32%) and lack of resources (23%).
CONCLUSIONS
Development of alternative indicators for trachoma surveillance and continued investment in trachoma programmes, particularly focused support in the most heavily affected populations, might increase enthusiasm for the feasibility of eradication.

Identifiants

DOI: 10.1136/bjophthalmol-2020-315815 PMID: 32855161 PMC: PMC8311100
pubmed: 32855161
pii: bjophthalmol-2020-315815
doi: 10.1136/bjophthalmol-2020-315815
pmc: PMC8311100
mid: EMS106913
doi:

Substances chimiques

Anti-Bacterial Agents 0
Azithromycin 83905-01-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1059-1062

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Surv Ophthalmol. 2002 Sep-Oct;47(5):500-9
pubmed: 12431697
Clin Infect Dis. 2018 Nov 28;67(12):1840-1846
pubmed: 29741592
PLoS Negl Trop Dis. 2009 Jun 16;3(6):e462
pubmed: 19529762
Clin Infect Dis. 2002 Sep 15;35(6):765-8
pubmed: 12203176
Am J Trop Med Hyg. 2019 Dec;101(6):1286-1295
pubmed: 31549612
Invest Ophthalmol. 1963 Oct;2:482-9
pubmed: 14069757
Lancet Infect Dis. 2019 Aug;19(8):815
pubmed: 31256954
Trop Med Int Health. 2010 Feb;15(2):168-72
pubmed: 20002619
Lancet. 2009 Mar 28;373(9669):1111-8
pubmed: 19329003
JAMA. 2006 Mar 8;295(10):1142-6
pubmed: 16522834
Lancet Infect Dis. 2005 Apr;5(4):194-6
pubmed: 15792732
Ophthalmology. 2020 Jan;127(1):11-13
pubmed: 31864470
Am J Trop Med Hyg. 2019 Oct;101(4_Suppl):68-73
pubmed: 31760975
PLoS Med. 2018 Aug 14;15(8):e1002633
pubmed: 30106956
PLoS Negl Trop Dis. 2009 Dec 22;3(12):e573
pubmed: 20027217
Ophthalmology. 2009 Nov;116(11):2047-50
pubmed: 19744717
Trans R Soc Trop Med Hyg. 2018 Dec 01;112(12):538-545
pubmed: 30265355
PLoS Negl Trop Dis. 2018 Dec 14;12(12):e0007027
pubmed: 30550537
BMJ. 2018 Nov 9;363:k4779
pubmed: 30413418
Lancet Infect Dis. 2019 Jan;19(1):e14-e25
pubmed: 30292480
PLoS Negl Trop Dis. 2009;3(2):e376
pubmed: 19190781
N Engl J Med. 2004 Nov 4;351(19):1962-71
pubmed: 15525721
JAMA Ophthalmol. 2017 Nov 1;135(11):1141-1146
pubmed: 28973295
PLoS Negl Trop Dis. 2012;6(11):e1873
pubmed: 23133684
Epidemics. 2011 Jun;3(2):119-24
pubmed: 21624783
PLoS Negl Trop Dis. 2019 Sep 5;13(9):e0007605
pubmed: 31487281
Bull World Health Organ. 1998;76 Suppl 2:22-5
pubmed: 10063669
Bull World Health Organ. 1987;65(4):535-46
pubmed: 3319270
Bull World Health Organ. 1999;77(6):461-6
pubmed: 10427930
PLoS Negl Trop Dis. 2013 Dec 05;7(12):e2562
pubmed: 24340111
Ophthalmic Epidemiol. 2018 Dec;25(sup1):1-2
pubmed: 30806531
N Engl J Med. 2008 Apr 24;358(17):1870-1
pubmed: 18434662
Nat Commun. 2018 Dec 21;9(1):5444
pubmed: 30575720
PLoS Negl Trop Dis. 2016 Feb 12;10(2):e0004462
pubmed: 26871898

Auteurs

Catherine E Oldenburg (CE)

Department of Ophthalmology, University of California, San Francisco, California, USA catherine.oldenburg@ucsf.edu.
Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
ORCID: 0000-0002-0763-399X

Solomon Aragie (S)

The Carter Center, Addis Ababa, Ethiopia.

Abdou Amza (A)

Faculté Des Sciences De La Santé, Université Abdou Moumouni De Niamey, Niamey, Niger.
Programme National De Santé Oculaire, Niamey, Niger.

Anthony W Solomon (AW)

Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
ORCID: 0000-0001-7101-6649

Jessica Brogdon (J)

F.I. Proctor Foundation, University of California, San Francisco, California, USA.

Benjamin F Arnold (BF)

Department of Ophthalmology, University of California, San Francisco, California, USA.
F.I. Proctor Foundation, University of California, San Francisco, California, USA.

Jeremy D Keenan (JD)

Department of Ophthalmology, University of California, San Francisco, California, USA.
Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
F.I. Proctor Foundation, University of California, San Francisco, California, USA.
ORCID: 0000-0002-7118-1457

Thomas M Lietman (TM)

Department of Ophthalmology, University of California, San Francisco, California, USA.
Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
F.I. Proctor Foundation, University of California, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Can we eradicate trachoma? A survey of stakeholders.
questionsmedicales.fr › Composés chimiques organiques › Lactones › Érythromycine › Azithromycine › Can we eradicate trachoma? A survey of stakeholders.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Éradication de maladie › Can we eradicate trachoma? A survey of stakeholders.
questionsmedicales.fr › Caractéristiques de la population › Santé › Santé mondiale › Can we eradicate trachoma? A survey of stakeholders.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes sur les soins de santé › Can we eradicate trachoma? A survey of stakeholders.
questionsmedicales.fr › Organisations et économie des soins de santé › Mise en oeuvre des programmes de santé › Can we eradicate trachoma? A survey of stakeholders.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Can we eradicate trachoma? A survey of stakeholders.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Can we eradicate trachoma? A survey of stakeholders.
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Services de médecine préventive › Can we eradicate trachoma? A survey of stakeholders.
questionsmedicales.fr › Maladies de l'oeil › Infections de l'oeil › Infections bactériennes de l'oeil › Conjonctivite bactérienne › Trachome › Can we eradicate trachoma? A survey of stakeholders.
questionsmedicales.fr › Organisations et économie des soins de santé › Organismes › Agences internationales › Nations Unies › Organisation mondiale de la santé › Can we eradicate trachoma? A survey of stakeholders.